Roy Jakobs was appointed internally to head connected care at Philips on 28 January, shortly before COVID-19 forced the first of many lockdowns around the world. The disruption prompted a rapid rethink of priorities, which has shown opportunities for lasting health care system change.
The best-laid plans earn individuals no plaudits when they go wrong, rather it is how well they manage through unexpected events (and even crises) that make the foundations on which future success is built.
Roy Jakobs was head of Royal Philips NV personal health businesses when last autumn he accepted group CEO Frans...
This week, the FDA announced a new head of its device evaluation office; synthetic genomics firm Constructive Bio landed $58m in funding; and Natera got a permanent injuction against NeoGenomics Labs' RaDaR assay.
Tim Schmid, executive VP and worldwide chairman of J&J MedTech, expects Shockwave, acquired in April, and Abiomed, purchased in late 2022, to be “long-term gems” for the company. Cardiovascular is among higher-growth segments where J&J has concentrated investments in recent years, along with robotic surgical systems.
The US FDA has published a trio of draft guidance documents for its Assessment Scheme for Conformity Program, which began as a pilot in September 2020 to capitalize on the role of standards in the regulation of medical devices.
Inari Medical is updating use instructions for a clot-removing catheter due to the potential for serious adverse effects, including death.
AdvaMed president Scott Whitaker said the group is focused on the need for tariff stability in conversations with the Trump administration. The organization remains optimistic about other policy areas. New chairman and ResMed CEO Mick Farrell laid out his five priorities.
Class III devices and panel-track supplements approved by US FDA’s Center for Devices and Radiological Health. Data derived from FDA.gov. Updated weekly.
AdvaMed president Scott Whitaker said the group is focused on the need for tariff stability in conversations with the Trump administration. The organization remains optimistic about other policy areas. New chairman and ResMed CEO Mick Farrell laid out his five priorities.
